33
Patients with stage
II/III ovarian cancer
Combination
platinum adjuvant
therapy
Single agent
carboplatin
Patients with stage
III ovarian cancer,
PS 0–2
Patients referred
to be assessed for
appropriate evidence-
based intraperitoneal
chemotherapy,
following optimal
debulking, where
there are resources
and expertise to
manage toxicities
Assess patients
for appropriate
evidence-based
targeted therapy
Without borderline
and micro-invasive
tumors, and not
suboptimal debulked
Targeted
therapy is not
recommended
on a routine
basis
No role for adjuvant
chemotherapy
Patients with
PS 0–2 and no
contraindications
Patients with
PS >2 and/or
contraindications
Intraperitoneal
chemotherapy and
targeted therapy
Basic Limited Enhanced
Patient
Category
Intervention
Category
Key
With high-risk
features
